In the United States, a uncommon illness is outlined as one affecting fewer than 1 in 200,000 individuals. While individually uncommon, over 7,000 known diseases collectively have an effect on greater than 400 million individuals globally.
Despite this, individuals residing with rare diseases (PLWRD) stay underserved and face numerous challenges, together with late diagnoses with penalties on long-term outcomes, few, if any, remedy choices, and illness programs which can be typically progressive, extreme, and life-limiting.
There are many causes that uncommon illness remedy growth has struggled to maintain tempo with broader indications. When contemplating the challenges of clinical trials, for instance, affected person populations are smaller and analysis and growth prices stay excessive, limiting the market and creating little financial incentive.
The mixed affect of the analysis itself alongside disparities in remedy entry locations a major burden on PLWRD, their family members, healthcare programs, and society. However, in 2025, the World Health Assembly voted unanimously to make uncommon illnesses a global health priority and known as for a 10-year world motion plan to be thought-about by 2028.
Technology Networks spoke with Rebecca Jansen, affiliate vp at Bora Pharmaceuticals, in regards to the challenges in uncommon illness drug growth and rising applied sciences that might rework the sphere.
Izzy Hirst (IH):
Can you inform us about your educational background and the way your profession developed?
Rebecca Jansen (RJ):
I’ve a level from the University of Minnesota, College of Biological Sciences. I’ve been within the pharmaceutical business for over 20 years, particularly working in manufacturing science and expertise, main inner and externally manufactured merchandise.
Over time, my profession expanded from supporting new product launches and expertise switch to overseeing broader growth capabilities. A core focus of mine is to make sure that merchandise should not solely developed efficiently however are additionally commercially viable and reliably manufactured.
Translating scientific innovation into one thing manufacturable, scalable, and accessible to sufferers, particularly these with very restricted remedy choices, is what continues to encourage me.
Can you describe the challenges confronted by pharmaceutical operations overlaying advanced, high-barrier medicine for specialty pharma and uncommon illnesses?
In uncommon illnesses, there are only a few therapeutic choices. Many instances, there’s just one remedy out there. Due to this, corporations wish to present world outreach, and producers have to be able to assist a number of regulatory company necessities throughout areas. This provides complexity to approval necessities and general provide technique.
Additionally, generally the route of administration can’t be a normal pill, relying on the affected person inhabitants and limitations with swallowing associated to the illness. That means flexibility in manufacturing expertise is required, akin to offering liquid formulations or powders for resuspension, particularly inside pediatric populations.
There can be the truth that affected person populations are sometimes small with excessive growth prices. From an operations standpoint, you want each specialised experience and the power to fabricate smaller-scale batches effectively. It isn’t just about growing a product, it’s about guaranteeing the event course of can constantly assist sufferers, even when volumes are small and regulatory expectations are advanced.
What limitations do sufferers with uncommon illnesses face when it comes to remedy accessibility, and the way do these limitations contribute to vulnerability?
The first barrier is the challenge of accurate diagnosis. As the illness is uncommon in nature, sufferers might undergo many evaluations and specialists earlier than lastly receiving the right analysis. In some instances, signs may be misinterpreted, which delays acceptable remedy. From there, they might solely have one remedy choice, and having access to that treatment shouldn’t be simple. It typically requires prior authorization from insurance coverage and finding a pharmacy that carries it, significantly if it’s a specialty product. Sometimes, a affected person might should accept compounding pharmacies for off-label use.
Compounding Pharmacies
Compounding pharmacies play a key position in guaranteeing remedy entry for sufferers with uncommon illnesses. After receiving authorization, they produce specialty drugs and tailor them to swimsuit particular person affected person wants, when this remedy is in any other case not accessible.
Costs are excessive, so medical insurance coverage is important. Many of those sufferers wouldn’t be capable to afford remedy with out it. When you mix delayed analysis, restricted choices, and price, it creates important vulnerability. For sure pediatric circumstances, even quick delays in remedy can have long-term developmental penalties, which is why bettering entry immediately impacts affected person outcomes. For us on the event aspect, that is the place pace to market comes into play—the extra effectively we will produce these drugs, the higher.
Can you describe some options which have been developed to beat these challenges?
Collaboration is important. Clinicians and oldsters typically establish unmet wants first. Our position is to convey formulation experience and manufacturing functionality to show these concepts into secure, scalable merchandise that really meet affected person necessities.
For instance, Upsher Smith is now a part of Bora Group and has a Promise of Support Program for a uncommon illness remedy utilized in childish spasms. It’s a novel partnership the place the developer works carefully with advocacy teams to pay attention to folks of sufferers and tailor options. Then, from a product perspective, a next-generation formulation was developed to make the treatment simpler to manage. This meant offering each a powder for reconstitution and a ready-to-use oral answer.
Before this development, dad and mom needed to have water bottles available to combine with the powder after which deal with their child—all whereas they have been actively seizing. I can’t think about how aggravating that might be. With this development, the treatment is able to use; no mixing is critical. This change could appear easy, however for caregivers administering treatment throughout a medical emergency, it considerably reduces stress and complexity.
Across all illness states, sufferers face inequitable entry to remedy. Why is that this particularly necessary to handle in uncommon illnesses?
It is so necessary for pharmaceutical corporations to supply significant assist for sufferers. Rare illness sufferers shouldn’t have many choices and sometimes want fast entry to remedy. Using the instance of infantile spasms, each day with out remedy will increase the danger of psychological and bodily developmental disabilities. When there is just one authorized remedy or very restricted alternate options, delays attributable to insurance coverage hurdles, provide challenges, or geographic limitations can have life-altering penalties.
In uncommon illnesses, inequity is amplified as a result of the affected person inhabitants is small. There could also be fewer specialists, fewer advocacy sources, and fewer general consciousness. That makes affected person assist packages and robust collaboration between producers and innovators much more important.
Looking forward, are there any rising applied sciences and improvements that you just anticipate will considerably enhance entry to remedies for people residing with uncommon illnesses?
I hope corporations will all the time take a look at advancing therapies to assist affected person adherence, whether or not that could be a ready-to-use oral answer or an extended-release formulation to lighten the remedy burden. Making therapies simpler to manage can considerably enhance real-world outcomes.
New expertise is advancing each day, from gene therapy to integration of 3D-printing in drug development, to solubility-enhancing applied sciences that enable us to formulate difficult molecules. Furthermore, nanoparticle and amorphous approaches are serving to tackle poorly soluble medicine that won’t have been viable prior to now. We are additionally seeing elevated curiosity in drug-device combos, which might scale back dosing complexity and enhance precision.
In addition, regulatory businesses are adapting evaluation timelines and communication pathways to assist corporations transfer extra effectively towards approval, significantly for life-saving and uncommon illness therapies.
When innovation focuses not solely on the molecule, but additionally on manufacturability and accessibility, that’s the place we see the best affect.